Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%-Reference-Cited by-同舟云学术

Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%

Published:2019-01-10 Issue:2 Volume:21 Page:321-329
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Owens David R.¹^ORCID,Landgraf Wolfgang²^ORCID,Frier Brian M.³^ORCID,Zhang Mei⁴,Home Philip D.⁵,Meneghini Luigi⁶^ORCID,Bolli Geremia B.⁷^ORCID

Affiliation:

1. Swansea University; Diabetes Research Group Cymru, College of Medicine; Swansea UK

2. Sanofi; Frankfurt Germany

3. The Queen's Medical Research Institute; University of Edinburgh; Edinburgh UK

4. Sanofi US; Bridgewater New Jersey

5. Department of Medical School, Institute of Cellular Medicine, Diabetes; Newcastle University; Newcastle upon Tyne UK

6. Department of Internal Medicine, Endocrinology; University of Texas Southwestern Medical Center and Parkland Health and Hospital System; Dallas Texas

7. Department of Internal Medicine; University of Perugia School of Medicine; Perugia Italy

Funder

Sanofi

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13607/fullpdf

Reference22 articles.

1. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2018 executive summary;Garber;Endocr Pract,2018

2. Standards of medical care in diabetes - 2018;American Diabetes Association;Diabetes Care,2018

3. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Davies;Diabetes Care,2018

4. A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin;Raccah;Diabetes Metab Res Rev,2017

5. Identification of barriers to insulin therapy and approaches to overcoming them;Russell-Jones;Diabetes Obes Metab,2018

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sex-difference of multifactorial intervention on cardiovascular and mortality risk in DKD: post-hoc analysis of a randomised clinical trial;Cardiovascular Diabetology;2024-08-05

2. Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study;Advances in Therapy;2024-03-21

3. Sex differences in type 2 diabetes: an opportunity for personalized medicine;Biology of Sex Differences;2023-12-13

4. Sex differences in type 2 diabetes;Diabetologia;2023-03-10

5. Quality improvement efforts in a safety net institution: Increased diabetes screening is associated with lower HbA1c at diagnosis and improved HbA1c outcomes in youth with type 2 diabetes;Pediatric Diabetes;2022-11-07